RCT Exudate Management Cutimed Sorbion Product Range

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-10

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The fluid handling capacity of superabsorbent dressings varies depending on the design and construction. The use of effective advanced wound dressings is a promising strategy to achieve adequate absorption of wound exudate and malodour promoting wound healing. The aim of the current study is to determine whether there is a difference in the clinical performance of exudate absorption with two commonly used CE-marked superabsorbent dressings when used on VLUs in routine wound care.

As primary objective the dressing´s absorption performance and its ability to prevent skin maceration and leakage of the wound dressing will be investigated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AQUACEL® Ag+ Extra™ vs Cutimed® Sorbact®

NCT07308678

Venous Leg Ulcer Diabetic Foot

COMPLETED

Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements

NCT03020446

Venous Wound Ulcers

TERMINATED NA

AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period

NCT05892341

Venous Leg Ulcer Diabetic Foot

COMPLETED NA

Study to Evaluate the Effect of Sorbion Sachet S Wound Dressing

NCT01319097

Pressure Ulcers

COMPLETED NA

Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg Ulcers

NCT05873257

Venous Leg Ulcer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Two assessors are blinded to evaluate some outcomes

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cutimed Sorbion products

Within this arm the Cutimed Sorbion (Cutimed® Sorbion® Sachet/Sana/Border) products will be used for exudate managment.

Group Type EXPERIMENTAL

Superabsorbent dressing application

Intervention Type DEVICE

Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate

Zetuvit (RespoSorb) products

Within this arm the comperator products Zetuvit® Plus/(RespoSorb® Super), Zetuvit® Plus Silicone/(RespoSorb® Silicone) and Zetuvit® Plus Silicone Border/(RespoSorb® Silicone Border) will be used for exudate management.

Group Type ACTIVE_COMPARATOR

Superabsorbent dressing application

Intervention Type DEVICE

Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Superabsorbent dressing application

Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant is informed about the trial, understands the nature of the study and provides written informed consent prior to study enrolment
2. Participant is mentally and physically able to participate in this study
3. Men, women, diverse ≥ 18 years
4. Participant complies with study visit schedule
5. Participant agrees to comply with all standard therapies (e.g., with regards to compression therapy)
6. Participant suffers from lower leg ulcer\* (including the ankle but not the feet) indicated to be treated with the study deviceinvestigational devices, requiring compression and fulfilling the following:
7. Ulcer is not younger than 4 weeks and not older than 1 year
8. Ulcer is ranging between 2 cm2 and 800 cm2
9. One side of the ulcer is not extending 40 cm
10. Depth of ulcer \< 2 cm
11. Ankle-brachial pressure index (ABPI) of \>0.8 and ≤1.3, measurement not older than 12 months \* Participants with more than one ulcer are eligible for inclusion, however only one ulcer per patient will be included in the study.

Exclusion Criteria

1. Participant already participates in this study with one ulcer (only one ulcer per participant is allowed)
2. Participant is expected not to be willing or able to follow the study outlines and requirements
3. Participant suffers from systemic infectious disease(s) known to negatively influence wound healing, such as AIDS
4. Participant is undergoing an immuno-compromising therapy, such as systemic antineoplastic drugs and/or systemic corticosteroids
5. Participant uses any medication that could potentially delay the wound healing ability
6. Participant is an employee (staff or student) of the hospital site (institute) or the sponsor or is in a dependent relationship with a member of site or sponsor staff, e.g. child, spouse etc.
7. Participant is pregnant or currently breastfeeding
8. Participant reporting (and/or suspected by investigator) addiction from alcohol or drugs or is substituted e.g., by Methadone

8\. Participant suffers from alcohol or drug addiction or is substituted e.g., by Methadone 9. Participant is or has been included in another clinical investigation with medical devices or pharmaceutical drugs at present or during the past 30 days 10. Participant with a history of sensitivity to any of the components of the study product 11. Participant whose leg ulcers are clinically infected (e.g., erysipelas) or malignant 12. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the trial 13. The ulcer has exposed bone, tendon, ligaments and/or joint 14. History of radiation at the study ulcer site 15. Participant's lesion is a primary skin cancer 16. Participant's lesion is the manifestation of a metastasis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No